Introduction
Notch3 belongs to a family of proteins essential for cellular differentiation in a variety of developing tissues. In mammals, there are four Notch receptors (Notch1-Notch4) and two families of ligands, Jagged (Jagged1 and 2) and Delta-like (Dll1, 3 and 4). Ligand binding results in two successive proteolytic cleavages by an ADAM-type metalloprotease and by a g-secretase, respectively (for review, see (Roy et al., 2007) ). The released Notch intracellular domain translocates to the nucleus, binds to transcription factor CSL (CBF1, Sel, Lag-1), and induces expression of target genes, such as the Hairy-enhancer of Split (HES) and hairy and Enhancer-of-split related with YRPW motif (Hey) gene families.
Aberrant activation of Notch proteins is associated with cancer phenotypes (Das et al., 2004; Curry et al., 2005; Duechler et al., 2005; Reedijk et al., 2005) . Notch3 is overexpressed in about 40% of non-small cell lung cancers, and suppression of Notch3 results in the loss of the malignant phenotype both in vitro and in vivo models (Haruki et al., 2005; Konishi et al., 2007) . Tumor suppression is enhanced when Notch inhibition is combined with epidermal growth factor (EGF) pathway inhibitors in vitro. These observations support the findings in both the development and the cancer literature that Notch and epidermal growth factor receptor-ras-mitogen-activated protein kinase (EGFR-ras-MAPK) pathways are interdependent. Whether ras enhances or antagonizes Notch signaling in development seems to be context dependent. In cancer, however, many studies have suggested that the ability of ras or Notch to transform cells depends on the cooperative relationship between them (Dievart et al., 1999; Fitzgerald et al., 2000; Weijzen et al., 2002; Haruki et al., 2005) .
The role of the Notch pathway in tumorigenesis also involves the regulation of the apoptotic pathway. The Bcl-2-related proteins are key regulators of apoptosis. There are three subfamilies, the prosurvival Bcl-2-like proteins, such as Bcl-2, Bcl-xL and Mcl-1, the proapoptotic proteins Bax and Bak, and the BH3-only proteins that share homology with the Bcl-2 family only in the BH3 region (Heiser and Hebrok, 2004) . The BH3only proteins function mainly as initiators of apoptosis. They are activated by cellular stress, such as DNA damage in the case of Noxa and Puma, or by growth factor deprivation in the case of Hrk and Bim. Other BH3-only proteins, such as Bid, are activated by death receptors via caspase-8 (Borner, 2003) . Recently, it has been reported that Bim is required to induce apoptosis in several cancer types, including lung cancer (Gomez-Bougie et al., 2005; Gong et al., 2007) . Little is known about the relationship between the Notch3 pathway and Bim regulation. As Bim is induced by growth factor deprivation, we hypothesize that the cross-talk between EGFR-ras and Notch3 modulates apoptosis through the regulation of Bim.
In this study, we demonstrate that Notch3 modulates apoptosis through the Bcl-2 protein family. We also provide evidence that the Notch3 and MAPK pathways modulate Bim to regulate apoptosis. Although Notch3 is known to regulate apoptosis through other pathways such as the nuclear factor-kB (NF-kB) pathway, to the best of our knowledge, this is the first study linking Bim to Notch3-dependent apoptosis in lung cancer.
Results
Notch3 modulates apoptosis through the regulation of phospho-extracellular signal-regulated kinase and Bcl-2-related proteins but has no effect on the Akt-PI3 K pathway Consistent with our earlier study, loss of Notch3 activity resulted in the downregulation of phospho-extracellular signal-regulated kinase, a member of the MAPK family. Interestingly, although Notch3 modulated the MAPK pathway, no effect on phospho-Akt, phosphoinositide 3-kinase (PI3 K), protein kinase C-a and Foxo3a was observed ( Figure 1a ). Notch3 affects the Akt-PI3 K pathway in some experimental systems but not others, suggesting that, unlike the MAPK pathway, cellular context is more important for the Notch3 modulation of the PI3K-pAkt pathway (Campos et al., 2002; Wang et al., 2007a) . Using Notch3 short interfering RNA (siRNA), we also observed that Notch regulates both pro-apoptotic and pro-survival proteins (Figure 1b ). Although no change was detected in Mcl-1 level, phospho-Bcl-2 (pBCl2) and Bcl-xL were downregulated in HCC2429 when the cells were transfected with Notch3 siRNA, compared with control siRNA. Conversely, the pro-apoptotic protein Bax expression was upregulated. Taken together, these observations are consistent with the hypothesis that Notch3 is oncogenic in lung cancer.
BH3-only proteins is a subset of the Bcl-2 family. They function as damage sensors and respond to distinct forms of cellular stress or DNA damage (Borner, 2003) . As the Notch pathway is known to cross-talk with the ras-MAPK pathway, and pro-apoptotic Bim is induced by growth factor deprivation, we hypothesized that Bim is the mediator in Notch3 regulation of apoptosis. This hypothesis is consistent with our earlier observation that Notch3-mediated apoptosis is enhanced in the presence of growth factor deprivation (Haruki et al., 2005) . In this study, Bim expression was increased after transfection with Notch3 siRNA (Figure 1c ). Phospho-BAD, a pro-apoptotic protein that is modulated by cytokines/ growth factors withdrawal, was similarly affected.
Puma functions as sensor for DNA damage and has been shown to be a direct target of p53-mediated apoptosis. However, Bid is a target of the death receptor In contrast, no change in the expression of Puma or Bid is seen. It is noteworthy that pBad is upregulated in Notch3 siRNA-treated cells compared with cells treated with siRNA control. Similar to Bim, cytokines and growth factors regulate pBad, further supporting previous observations of significant cross-talk between Notch and epidermal growth factor receptor (EGFR) pathway. (d) In comparison with siRNA control, an increase of Bim mRNA was observed when lung cancer cell line HCC2429 was transfected with Notch3 siRNA, suggesting that Notch3 regulated Bim transcriptionally. In all siRNA experiments, non-silencing siRNA was used as control.
Notch3 cooperates with the EGFR pathway J Konishi et al ligands. No change in the levels of Puma and Bid was observed when tumor cells were transfected with Notch3 siRNA, suggesting that in some lung cancers Notch3dependent apoptosis is not mediated by p53 or the death receptors, but by the modulation of growth factors and cytokines. We detected significantly higher Bim mRNA expression in tumor cells transfected with Notch3 siRNA, compared with siRNA control (Figure 1d ). It is known that the Bim promoter possesses binding sites for Foxo3a, Mybs, and c-Jun, and mutation of any one of these sites abolishes Bim transcription in response to growth factor deprivation (Biswas et al., 2007) . As we have shown that Notch3 has no effect on Foxo3a, transcriptional regulation of Bim by Notch3 is indirect and more likely through c-jun and the ras-MAPK pathway.
Inhibition of Notch3 with siRNA induces apoptosis
Inhibition of the Notch pathway by either a dominantnegative receptor or by the g-secretase inhibitor, MRK-003, results in tumor apoptosis (Haruki et al., 2005) . As both the dominant-negative receptor and g-secretase inhibitor potentially target all of the Notch family receptors, we used the small interference RNA (siRNA) system to determine whether these observations are specific to Notch3. Apoptosis markers such as cleaved poly (ADP-ribose) polymerase and cytochrome c are induced by Notch3 siRNA (Figure 2a ). Furthermore, caspase-3 activity was enhanced in lung cancer cells treated with Notch3 siRNA ( Figure 2B ). Although alterations in apoptotic markers poly (ADP-ribose) polymerase and cytochrome c were observed, no change in apoptosis was detected with annexin V staining when cells were maintained in 10% fetal calf serum ( Figure 2C ). However, in the presence of growth deprivation, the percentage of apoptotic cells was significantly increased in Notch3 siRNA-treated cells compared with vector control. This observation is consistent with our previous studies with the g-secretase inhibitor MRK-003 and Notch3 dominant negative, in which apoptosis was seen in serum-free conditions (Haruki et al., 2005; Konishi et al., 2007) . These results demonstrate that although Notch3 can modulate many components of apoptosis, such as Bcl-xL and Bax in full-serum conditions, a noticeable effect on apoptosis requires growth factor deprivation.
Bim is necessary for induction of apoptosis in Notch3 knockout cells
To determine whether Bim is necessary for Notch3dependent apoptosis, we used Bim siRNA to suppress Bim in HCC2429 cells transfected with Notch3 siRNA. The loss of Bim abrogated the induction of poly (ADPribose) polymerase by Notch3 siRNA (Figure 3a ). In further support of our hypothesis, we observed that Bim knockdown abolished Notch3 siRNA-induced apoptosis in the absence of serum compared with vector control, suggesting that the effect of Notch3 on apoptosis is dependent on Bim (Figure 3b ). A small increase in apoptosis was detected in Bim-negative cells in both serum-free and 10% fetal calf serum conditions. Interestingly, Bim downregulation also resulted in the downregulation of Notch3, suggesting a feedback loop existed between the two pathways. 
Effect of Notch3 on Bim depends on intact MAPK signaling
To better define the interaction between Notch3 and EGFR-ras-MAPK pathways in Bim modulation, we examined the effects of the MEK inhibitor, U0126, and the EGFR inhibitor, AG1478, on lung cancer cells treated with Notch3 siRNA. Interestingly, Bim expression is induced with the MEK inhibitor U0126, whereas the added loss of Notch3 signaling did not augment Bim expression ( Figure 4a ). One explanation for this observation is that the effect Notch3 has on Bim is dependent on intact MAPK signaling and that inhibiting Notch3 by siRNA is not of added benefit. However, when HCC2429 cells were treated with both Notch3 siRNA and AG1478 at 5 mM, Bim expression was induced significantly compared with Notch3 siR-NA, U0126 or AG1478 alone (Figure 4b) . The Akt-PI3 K pathway regulates Bim through phosphorylation of the transcription factor Foxo3a (Urbich et al., 2005) . Thus, inhibiting both Notch3 and EGFR synergistically affects Bim through both Foxo3a and MAPK signaling.
To confirm that Notch3 regulates Bim through MAPK, we transfected activated Notch3 into COS cells treated with either U0126 or AG1478. As expected, U0126 prevented Bim suppression by activated Notch3, further supporting our contention that the anti-apoptotic effect of Notch3 is MAPK dependent (Figure 4c ). However, inhibition of EGFR with AG1478 could only partially reverse the effect of activated Notch3 on Bim expression despite near suppression of phosphoextracellular signal-regulated kinase, suggesting that Bim is also modulated by a MAPK-independent pathway (Figure 4d ).
g-Secretase and EGFR tyrosine kinase inhibition enhance anti-tumor activity in vivo and Bim expression
We previously observed that in vitro combination of g-secretase inhibitor, MRK-003, and the EGFR tyrosine 
Figure 4
Notch3 and epidermal growth factor receptor-rasmitogen-activated protein kinase (EGFR-ras-MAPK) pathways cooperate in regulating Bim expression. (a) Bim is upregulated when HCC2429 cell line was transfected with Notch3 short interfering RNA (siRNA) as compared with control at 0 times, whereas inhibition of Notch3 signaling does not increase Bim expression on treatment with U0126 alone at both 6 and 24 h, suggesting that Notch3 regulates Bim expression mainly through phospho-extracellular signal-regulated kinase (pERK). (b) AG1478 alone slightly diminishes Bim expression. However, treatment with both AG1478 and N3 siRNA results in the synergistic induction of Bim, compared with either treatment alone. Inhibition of pERK and EGFR with U0126 (c) and AG1478 (d), respectively, preventing Notch3-dependent suppression of Bim, supporting the hypothesis that modulation of Bim and apoptosis in lung cancer by Notch3 is dependent on intact EGFR-ras-MAPK signaling.
Notch3 cooperates with the EGFR pathway J Konishi et al kinase inhibitor (AG1478) was more effective in inhibiting tumor growth than either agent alone (Konishi et al., 2007) . To determine whether the combination of g-secretase inhibitor, MRK-003, and the EGFR tyrosine kinase inhibitor, erlotinib, also enhances tumor activity in vivo, we used a xenograft model. The combination of MRK-003 and erlotinib significantly reduced tumor size compared with either single agent alone (Figure 5a ). We also noted that the combination of MRK-003 and erlotinib resulted in greater expression of Bim in the mouse tumors compared with either agent alone (Figure 5b) . Given the role of Notch pathway in angiogenesis, we also measured microvessels density (data not shown). No change in tumor microvessels density was observed, supporting the hypothesis that mechanism of tumor inhibition in vivo involves Bim modulation. Finally, whether this effect is due to Notch inhibition is uncertain because of the non-specificity of g-secretase inhibitor. However, we previously have demonstrated that loss of Notch3 rendered the gsecretase inhibitor ineffective, suggesting that at least in our lung cancer model, the antitumor effect may be Notch3 dependent (Konishi et al., 2007) .
Discussion
Similar to Notch, the Bcl-2 protein family members have central roles in both development and cancer, facilitating strict organ morphogenesis during embryonic development and maintenance of tissue homeostasis. These proteins regulate programmed cell death through the integration of diverse extracellular and intracellular death signals. In this study, we demonstrated that the loss of Notch3 resulted in downregulation of prosurvival proteins, Bcl-2 and Bcl-xL, and in upregulation of the pro-apoptotic protein Bax, as well as the BH3-only proteins Bim and Bad. In tumorigenesis, activated Notch3 has been shown to induce T cell leukemia through the constitutive activation of NF-kB (Bellavia et al., 2000) . Activated Notch1 has been shown to inhibit p53-mediated apoptosis (Bocchetta et al., 2003; Beverly et al., 2005) . In this study, we examined the effect of Notch3 on both the NF-kB pathway and p53 using Notch3 siRNA. Although our findings indicate that Bim is a target of Notch3 signaling, we were unable to discern appreciable changes in levels of p53 or NF-kB-related proteins (data not shown), suggesting that the role of Notch3 in apoptosis is distinct, and context dependent.
Bim is a BH3-only member of the Bcl-2-like family of proteins. Loss or withdrawal of cytokines and growth factors specifically induce its expression. Once Bim is activated, it binds and inactivates Bcl-2-like prosurvival proteins, leading to cytochrome c release from mitochondria and caspase activation. Furthermore, Bim is required to mediate EGFR inhibitor-induced apoptosis in lung cancer cells, also supporting a significant interaction between Bim and the EGFR-ras-MAPK pathway (Costa et al., 2007; Gong et al., 2007; Wang et al., 2007b) . In this study, we demonstrate not only that the loss of Notch3 results in upregulation of Bim, but also that Bim expression is further enhanced when both the EGFR and Notch3 pathways were inhibited. This finding provides additional evidence for the crosstalk between the EGFR and Notch3 in modulating apoptosis.
Although Notch signaling regulates apoptosis through the NF-kB and p53 pathways in some cells, Bim seems to be necessary for the induction of Notch3dependent apoptosis in lung cancer. This finding is supported by the recent observation that Notch inhibition using a g-secretase inhibitor upregulates Bim in malignant melanomas (Qin et al., 2004) . Although it is possible that this effect is unrelated to Notch inhibition Figure 5 Combination of Notch inhibition with MRK-003 and EGFR inhibition with erlotinib has greater antitumor effect in vivo and enhances Bim expression. (a) H460 cells were inoculated subcutaneously into nude mice and treatment was initiated when tumors were palpable. Treatment with the combination of erlotinib and MRK-003 resulted in the lowest rate of tumor growth, compared with treatment with either alone. The asterisk (*) denotes statistical significance, Po0.05 when comparing treatment with the combination vs MRK-003 alone. The difference between erlotinib alone treatment and the combination is statistically significant across all time points except for day 1. (b) Bim expression was markedly higher in tumor treated with MRK-003 and erlotinib than either MRK-003 or erlotinib alone. Consistent with our previous observation, no change in the level of Mcl-1 was noted.
due to the potential lack of specificity of the g-secretase inhibitors, our siRNA data suggest that Bim upregulation results from specific Notch3 knockdown, and that Notch-induced apoptosis is indeed dependent on this upregulation of Bim.
The withdrawal of growth factors results in the induction of Bim through either of the two major EGFR-dependent pathways: the Raf-MAPK and Akt-PI3 K (Shinjyo et al., 2001) . The Akt-PI3 K pathway is known to negatively affect Bim through downregulation of Foxo3a. In our study, no change in pAkt or pFoxoa3 was noted in the lung cancer cell lines transfected with Notch3 siRNA, indicating that Notch3 regulates Bim expression through the MAPK pathway and not the Akt pathway. Activated Notch3 was unable to rescue U0126-induced apoptosis, providing further evidence that Notch3 modulation may be entirely dependent on MAPK pathway. This contention is consistent with our previous findings that Notch3 regulates the MAPK activation through modulating MAPK phosphatase.
In summary, we have characterized one mechanism using which Notch3 performs an important role in the biology of cancer through the modulation of apoptosis. Although the crucial role of Notch signaling in apoptosis has been well established in the context of cancer as well as development, the mechanism by which Notch3 affects apoptosis in lung cancer remained obscure to date. In this study, we provided evidence that Bim is necessary for Notch3-dependent apoptosis and that the effect of Notch3 on Bim is through MAPK regulation.
Finally, we previously observed a cooperative relationship between the Notch3 pathway and the EGFR pathway in maintaining the tumor phenotype. Our data have shown that this cooperative relationship also involves the modulation of Bim. Interestingly, Bim expression is upregulated in lung cancer cell lines sensitive to inhibitors of EGFR signaling, but not in resistant cell lines (Gong et al., 2007) . Taken together, these observations suggest that the concomitant inhibition of Notch and EGFR pathways represents a rational strategy for promoting apoptosis in lung cancer and potentially overcoming treatment resistance.
Materials and methods

Cell lines and inhibitors
The Notch3-expressing lung cancer cell line, HCC2429, was established as previously described (Dang et al., 2000) . The non-small cell lung cancer cell line H460 and COS cell line were obtained from American Type Culture Collection (ATCC) and maintained in RPMI supplemented with 10% fetal calf serum. Activated Notch3 was created previously and cloned into pBabe retroviral vector. AG1478 and U0126 were obtained from Calbiochem (La Jolla, CA, USA), and erlotinib was obtained from Genetech (San Francisco, CA, USA). The formulation and the in vivo dosing of g-sectretase inhibitor, MRK-003, was provided by Merck & CO, Inc. (Whitehouse Station, NJ, USA) and was described previously (Lewis et al., 2007) .
Notch3 and bim siRNAs
Notch3-overexpressing cell lines, HC2429 and H460, were seeded at 1.5 Â 10 5 cells per 6-well plate the day before transfection. The Notch3 siRNA sequence is 5 0 -CACCU AUAACUGCCAGUGC-3 0 and was synthesized by Qiagen (Valencia, CA, USA). Cells were transfected with 100 nmol/l siRNA in Opti-MEM medium (Invitrogen, Calsbad, CA, USA) using LipofectAMINE 2000 (Invitrogen) according to the manufacturer's recommendation. The efficiency of siRNA transfection was measured with western blot analysis. Bim siRNA (catalog number M-004383-01-0010) was purchased from Dharmacon Research (Lafayette, CO, USA). An unspecific (non-silencing) siRNA against the target sequence 5 0 -AATTCTCCGAACGTGTCACGTTT-3 0 (cat. no. 80-11310, Xeragon) was used as controls.
Caspase-3 cellular activity HCC2429 cells was transfected with Notch3 siRNA or control as described above. After 24 or 48 h, cells were collected in lysis buffer, and cell extracts were used to determine caspase-3 activity, using the Caspase-3 Cellular Activity Assay Kit (Calbiochem). Caspase-3 activity was measured in cell lysates in the presence and absence of Caspase-3 inhibitor at 0.1 mM final concentration.
Apoptosis analysis
Cells transfected with Notch3 siRNA for 48 h were maintained in 10% fetal calf serum-supplemented RPMI or serum-free medium. These cells were stained with fluorescein isothiocyanate-conjugated annexin V and propidium iodide using annexin V-fluorescein isothiocyanate Apoptosis Detection kit (Calbiochem). The percentage of apoptotic cells was determined with a Beckman Coulter FACSCalibur Flow Cytometer (Beckman Coulter, Inc., Fullerton, CA, USA). In dual Notch3 and Bim siRNA transfection experiments, cells were transfected with Bim siRNA 24 h after Notch3 siRNA transfection. At 24 h after Bim siRNA transfection, cells were collected and analysed for apoptosis, as described above. Caspase-3 activity was measured using the Caspase-3 Cellular Activity Assay Kit (Calbiochem) according to manufacture's recommendation.
RNA extraction and real-time PCR
Total RNA was extracted with TRIzol (Invitrogen) from HCC2429 cells 24 h after transfection of either Notch3 siRNA or control siRNA. RNA was reverse transcribed with the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Real-time PCR was performed with the iQ5 multicolor Real-Time PCR detection system (Bio-Rad). A volume of 50 ml mixture was used for reaction, which contains 5 ml cDNA sample (0.5-1 mg/ml), 300 nM forward primers for Bim (5 0 -GCAGATATGCGCCCAGAGAT-3 0 ) or b-actin (5 0 -ATGGCTCCGGTATGTGCAA-3 0 ), 300 nM reverse primers for Bim (5 0 -AAGCGTTAAACTCGTCTCCGATA-3 0 ) or b-actin (5 0 -TGTCTTTCTGGCCCATACCAA-5 0 ), and 25 ml SYBR Green Supermix (Bio-Rad). After incubation at 50 1C for 2 min followed by an incubation at 95 1C for 10 min, the reaction was carried out for 40 cycles of the following: 95 1C for 15 s and 60 1C for 1 min. The threshold cycle value (C t ) was obtained using the iCycler Optical system interface software. Mean C t value for Bim was calculated from triplicate measurements and normalized with the mean C t value for the control gene for b-actin.
Antibodies and western blot analysis
Notch3 was detected using a rabbit polyclonal antibody at 1:500 dilution (Orbigen, San Diego, CA, USA). The rabbit antibodies against poly (ADP-ribose) polymerase, Bcl-xL, phosho-Bcl-2, Puma, BAX, phospho-extracellular signal-regulated kinase, ERK, phospho-Akt, Akt, PI3 K and PKA C-a were purchased from Cell signaling Technology (Danvers, MA, USA). The rabbit antibodies against Mcl-1 and Bim were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Calbiochem, respectively. The rabbit antibodies against phospho-Foxo3a and Foxo3a were from Millipore (Billerica, MA, USA). Monoclonal cytochrome c antibody was obtained from BD Biosciences (San Jose, CA, USA). Proteins were stained with Ponceau S to confirm equal loading of in each analysis. For western blot analysis of MAPK, Akt, PI3 K and PKA-Ca activation, cells were transfected with Notch3 siRNA before serum deprivation and maintained in serum-free medium for 24 h before the addition of serum. The cells were collected after designated time intervals.
In vivo tumorigenicity Athymic 4-6-week-old female nude mice (nu þ /nu þ ) were used for the tumor xenograft models. H460 (1 Â 10 6 cells suspended in 200 ml of phosphate buffered saline) was inoculated subcutaneously into the right posterior legs of the mice. Treatment was initiated when tumors were palpable. Erlotinib (100 mg/kg) was administered orally every other day to the mice alone or in combination with MRK-003 (150 mg/kg) given daily for 3 days followed by 4 days off. Erlotinib was diluted in 1% methylcellulose/0.1% Tween 80. MRK-003 was diluted in 0.5% methylcellulose. Tumors were measured every 2 days using a caliper. Tumor volume (TV) was calculated using the formula: TV ¼ (Length) Â (Width) 2 /2. Percentage tumor volume (% TV) on day X was calculated as: %TV ¼ (tumor volume on day X/tumor volume on day 1) Â 100.
Statistical analyses
The size of implanted tumors at different time points after treatment was compared with that of control groups. Unless specifically stated, statistical inference in comparative experiments both in vivo and in vitro was obtained using unpaired, two-sided Student's t-test. For all determinations, the differences were considered significant when P-value was o0.05.
